Why GW Pharmaceuticals Isn’t Moving, Despite a Big First for the FDA
GW Pharmaceuticals won an FDA approval for its cannabis-derived drug, but shares were relatively muted on Thursday.
All Work
Chris Lange
Why Helios and Matheson Analytics Is Crashing
Helios Mathseson Analytics saw its shares pull back massively on Thursday after the company said it will be conducting a secondary offering to raise funds.
Procter & Gamble Earnings and Acquisition Not Enough for Investors
Procter & Gamble made a couple big announcements on Thursday that were met by investor remorse.
Aceto Has a Heart Attack
There is a lot going on for Aceto in its latest update, and most of it is not good news. Amid credit negotiations, there are also changes at the highest level of management, making…
Philip Morris Earnings Up in Smoke
Philip Morris reported mixed first-quarter financial results before the markets opened on Thursday.
Why American Express Is Rallying
American Express Co. (NYSE: AXP) released its first quarter financial results after the markets closed on Wednesday. The company said that it had $1.86 in earnings per share (EPS) on $9.72 billion in revenue,…
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a mixed day for the broad U.S. markets. It’s possible that all three major indices would have notched a gain on the day if only IBM was thrown out. Big Blue posted…
Will Bed Bath & Beyond Be Put to Sleep?
It seems that things are only getting worse for Bed Bath & Beyond after Standard & Poor’s downgraded its credit rating again.
Why Amex Could Be Poised for a Strong Q1
We shouldn’t expect another big tax charge this quarter, and that’s one reason to be optimistic. However, there are plenty of other factors that could bring shares down. The stock could really go anywhere…
The FDA Strikes Again at Calithera Biosciences
Calithera Biosciences receives a Fast Track designation for its kidney cancer treatment, sending shares higher.
Is This the Turnaround Teligent Has Been Waiting For?
Teligent watched its shares make a solid gain on Wednesday after the firm announced a key approval from the FDA.
Rigel Pharmaceuticals Gets No Boost From FDA Approval
Rigel Pharmaceuticals shares retreated early Wednesday despite an approval from the FDA for its treatment of thrombocytopenia.
Does This Feel Like a Record Quarter for Morgan Stanley?
Morgan Stanley released a better-than-expected first-quarter earnings report before the markets opened on Wednesday.
Why IBM Earnings Aren’t Enough
International Business Machines Corp. (NYSE: IBM) reported its first quarter financial results after the markets closed on Tuesday. The company said that it had $2.45 in earnings per share (EPS) on $19.1 billion in…
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was another consecutive positive day for the broad U.S. markets. All three major indices notched a gain of at least nearly 1%. Although the averages performed well in the session, crude oil was…
Why GW Pharmaceuticals Could Be an FDA First
GW Pharmaceuticals shares saw a solid gain on Tuesday after the FDA released some briefing documents pertaining to an upcoming approval meeting. Needless to say, investors are taking this as a positive sign.
What to Expect When IBM Reports After the Close
IBM is scheduled to release its first-quarter financial results after the markets close on Tuesday.
Is This Move by Roku a Home Run?
Roku shares made a solid gain on Tuesday after it was announced that the company would be taking on another partner.
Why Now Is the Best Time for Bellicum to Raise Cash
Bellicum Pharmaceuticals shares pulled back on Tuesday after the firm announced that it would be conducting a secondary offering to raise some cash.
Johnson & Johnson Earnings Just Par for the Course
Johnson & Johnson (NYSE: JNJ) reported its first quarter financial results before the markets opened on Tuesday. The company said that it had $2.06 in earnings per share (EPS) on $20.01 billion in revenue,…